Core Insights - The company experienced record growth in clinical MRD volumes during Q3, particularly with the Signatera product, which showed significant quarter-on-quarter growth compared to Q2 [2] - There is ongoing interest from physicians in ordering the Signatera test for both new patients and for monitoring existing patients at risk for recurrence, indicating strong market demand [2] - Growth is being fueled by clinical data, including a new publication on IMvigor011 related to muscle invasive bladder cancer and strong colorectal data released earlier in the year [3]